市场监管总局：禁止武汉用通收购山东华泰制药股权

Core Viewpoint - The State Administration for Market Regulation has prohibited Wuhan Yitong Pharmaceutical Co., Ltd. from acquiring shares of Shandong Huatai Pharmaceutical Co., Ltd. due to antitrust concerns, emphasizing the need to maintain competition in the market for hydrochloride poppy alkaloid injection [1][2] Group 1 - The acquisition was deemed to have an exclusionary and restrictive effect on competition in the hydrochloride poppy alkaloid injection market in China [1] - Wuhan Yitong is required to transfer its indirect holdings in Shandong Huatai Pharmaceutical to an unrelated third party by January 22, 2026, and must not participate in the management of Shandong Huatai during this period [1] - If the share transfer is not completed by the deadline, Wuhan Yitong must apply to the market regulator for an extension and provide reasons for the delay [1] Group 2 - By September 30, 2025, Wuhan Yitong must terminate its agency agreement for hydrochloride poppy alkaloid raw materials with Qinghai Pharmaceutical and cannot execute related agreements until this is resolved [2] - The ultimate controller of Wuhan Yitong has committed not to engage in any future operator concentration in the fields of hydrochloride poppy alkaloid raw materials and injections [2] - The market regulator retains the authority to supervise and inspect Wuhan Yitong and its ultimate controller's compliance with these obligations [2]